Forbion’s Post

View organization page for Forbion, graphic

13,544 followers

We are pleased to announce that our via our Forbion Growth Opportunities Fund II, we have co-led a $100M Series A financing round for Navigator Medicines, Inc., a leading innovator in biologics for immune regulation and restoration. The funding will accelerate the development of Navigator’s lead asset, NAV-240, a bispecific antibody targeting OX40L and TNFα, currently in Phase 1 development for complex autoimmune diseases. Additionally, the investment will support Navigator’s broader pipeline of OX40L-targeted therapies. Forbion General Partner Wouter Joustra will join Navigator’s Board of Directors, and Forbion Principal Mathias Vinther will join as Board Observer. Click on the following link to learn more: https://lnkd.in/eDrqg7Mf #lifesciences #biotech #funding #seriesA #forbion #financing #autoimmune #biologics Marc-Olivier Turgeon Audrey Cacaly

  • No alternative text description for this image

To view or add a comment, sign in

Explore topics